| Document |
Document Title |
|
WO/2018/176150A1 |
Novel methods for isolating fish roe/egg extracts, notably a coagulum and a sediment extract, enriched in phospholipids and omega-3 fatty acids are described. Novel compositions comprising omega-3 polyunsaturated fatty acids and micronut...
|
|
WO/2018/176134A1 |
The present disclosure relates to compounds for use as electrode additives or as salts in electrolyte compositions, and their methods of preparation. The majority of compounds are anions of imidazoles bearing a sulphonyl or a carbonyl gr...
|
|
WO/2018/183112A1 |
The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycar...
|
|
WO/2018/177889A1 |
The present invention relates to novel modified macrocyclic compounds with improved tolerability of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of...
|
|
WO/2018/175927A2 |
This application pertains to orthogonally protected esters of peptide nucleic acid (PNA) monomers, which ester groups can be removed under conditions that permit typical backbone and side chain acid- and base-labile protecting groups to ...
|
|
WO/2018/172852A1 |
The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and co...
|
|
WO/2018/173882A1 |
Provided is a cyclic azine compound having exceptional heat resistance, a long service life in an organic electroluminescent element, and exceptional low-voltage drive properties or luminous efficiency. A cyclic azine compound having a s...
|
|
WO/2018/175670A1 |
Small molecule inhibitors are claimed that selectively target the hemopexin domain of matrix metalloproteinase 9 (MMP-9) and do not inhibit the protease's catalytic functions. A method of treating cancer in a patient in need thereof with...
|
|
WO/2018/172250A1 |
The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprisi...
|
|
WO/2018/166932A1 |
The present invention relates to arylamine derivatives which are substituted with diazanaphthalene groups, in particular for use in electronic devices. The invention further relates to a method for producing the compounds according to th...
|
|
WO/2018/170306A1 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
|
WO/2018/167468A1 |
The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the matura...
|
|
WO/2018/167187A1 |
The invention relates to a class of 5-carboxamide-2-thiobarbituric acid derivatives which inhibits human type II topoisomerase (topoII) enzyme and to use thereof as medicaments especially for blocking the proliferation of cancer cells an...
|
|
WO/2018/163077A1 |
The invention relates to indanyl compounds, their pharmaceutically acceptable salts thereof, processes for their preparation and pharmaceutical compositions comprising the same for the treatment, management and /or lessening severity of ...
|
|
WO/2018/157842A1 |
The present invention provides a use of 2-(substituted phenylamino)benzoic acid FTO inhibitor in treating leukemia.
|
|
WO/2018/159515A1 |
Provided is a method for producing a pentafluorosulfanyl aromatic compound represented by general formula (3), Ar-(SF5)k, (in the formula, Ar is a substituted or unsubstituted aryl group or heteroaryl group, and k is an integer between 1...
|
|
WO/2018/157843A1 |
The preparation method provides 2-(substituted benzene matrix) aromatic formate FTO inhibitor, a preparation method therefor, and applications thereof. Specifically, disclosed in the present invention are a 2-(substituted benzene matrix)...
|
|
WO/2018/157813A1 |
The present invention relates to a series of tricyclic compounds and the use thereof as receptor agonists of sphingosine 1-phosphate subtype 1 (S1P1), and in particular relates to compounds as shown in formula (I) or pharmaceutically acc...
|
|
WO/2018/157981A1 |
The present invention relates to triarylamine compounds of general formula (I). The present invention further relates to methods for producing said compounds, oligomers, polymers or dendrimers and to formulations containing said compound...
|
|
WO/2018/153379A1 |
A pharmaceutical composition comprising N-((5-((5-chloro-4-((naphthalene -2-yl)amino))pyrimidine-2-yl)amino)-2-((N-methyl-N-dimethyla
minoethyl)amino)-4-methoxypheny)acrylamide, and a preparation method for the pharmaceutical composition.
|
|
WO/2018/033642A9 |
The present invention relates to a compound of formula (I): wherein L is an optionally substituted heterocyclic group excluding unsubstituted monocyclic pyridine groups; wherein a is 0, 1 or 2; wherein R1 is H or with R2 is a bond; where...
|
|
WO/2018/151633A1 |
The present invention relates to a method for producing a compound of formula I, where B is, independently, hydrogen or [see appropriate figure], wherein no more than one B is hydrogen; D is NR1 or O; R1 is H, R, C1-C4 alkyl, unsubstitut...
|
|
WO/2018/151681A1 |
The present invention relates to pyrimidine compounds and compositions for treating tuberculosis. These compounds may be used to target the F1 domain of F-ATP synthase and may be used with bedaquiline or 6-chloro-2-ethyl-N-[[4-[4- [4-(tr...
|
|
WO/2018/148856A1 |
The present invention provides a compound of the Formula (1) below pharmaceutically acceptable salts of the compound of Formula (1), methods of treating patients for liver disease, and processes for preparing the compounds.
|
|
WO/2018/151520A1 |
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure has a high glass transition temperat...
|
|
WO/2018/151985A1 |
The present invention provides compounds of the formula below, pharmaceutically acceptable salts of the compounds, methods of treating patients for liver disease, and processes for preparing the compounds.
|
|
WO/2018/147555A1 |
The present invention relates to: a method for preparing a 4,5-diamino-substituted pyrimidine derivative represented by chemical formula (1) defined in claim 1, the derivative being an intermediate for preparing a cephalosporin derivativ...
|
|
WO/2018/143403A1 |
Provided is a novel compound or salt thereof that induces degradation by autophagy of an intracellular molecule. In this compound, a ligand having activity to bind to an intracellular molecule and a structure having activity to induce au...
|
|
WO/2018/140512A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (I) or a pharmaceutically acceptable salt, isotopic form, stereoisomer or prodrug thereof, wherein A, B, X,...
|
|
WO/2018/132326A1 |
Heterocyclic compounds of Formula (I) shown herein. Also disclosed is a pharmaceutical composition containing one of the heterocyclic compounds. Further disclosed are methods of using one of the heterocyclic compounds for mobilizing hema...
|
|
WO/2018/131690A1 |
[Problem] To provide a novel agrochemical, especially a novel herbicide. [Solution] A ketone or oxime compound represented by formula (1), and a herbicide which contains this compound. (In the formula, B represents B-1 or B-2; Q represen...
|
|
WO/2018/130625A1 |
The present invention relates to novel substituted benzene disulfonamides, as well as pharmaceutical compositions containing at least one of these substituted benzene disulfonamides together with at least one pharmaceutically acceptable ...
|
|
WO/2018/128390A1 |
The present invention relates to a method for producing a 5-(3,6-dihydro-2,6-dioxo-4-trifluoromethyl-1(2H)-pyrimidinyl
)phenylthiol compound. The production method according to the present invention enables provision of stable yield and ...
|
|
WO/2018/128387A1 |
The present invention relates to a method for producing a 3-arly uracil compound. The production method according to the present invention can efficiently produce a 3-arly uracil compound by reducing a reaction time for the production of...
|
|
WO/2018/128720A1 |
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
|
|
WO/2018/125961A1 |
The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method o...
|
|
WO/2018/124000A1 |
The present invention addresses the problem of providing a compound that, when used in the treatment of cystic fibrosis, which is caused by a mutation of a cystic fibrosis transmembrane conductance regulator (CFTR), which is a kind of ch...
|
|
WO/2018/122775A1 |
The application is directed to compounds of formula (I): and their salts and solvates, wherein R1, R2, R3, A1, A2, A3, and n are as set forth in the specification, as well as to a method for their preparation, pharmaceutical compositions...
|
|
WO/2018/124088A1 |
Provided are novel pest control agents, in particular, a bactericide and a nematicide. An alkylphenyl-substituted amide compound represented by formula (I) [wherein: G1 stands for a structure represented by G1-2, G1-3, G1-4, etc.; X1 sta...
|
|
WO/2018/122559A1 |
The present invention relates to compounds which are of use in the field of agriculture as herbicides. The invention also relates to methods of using said compounds and compositions comprising said compounds.
|
|
WO/2018/121758A1 |
Disclosed is a novel quinazoline compound. Specifically, disclosed are a compound represented by the formula (I) and a pharmacologically acceptable salt.
|
|
WO/2018/113584A1 |
Provided are an FGFR4 inhibitor having the structure of formula (I), and a preparation method therefor and the use thereof. The compound has a very strong inhibitory effect on FGFR4 kinase activity and has a very high selectivity, and ca...
|
|
WO/2018/114476A1 |
The present invention relates to an amidine containing at least one structure unit of formula (I) and to the use thereof as a catalyst for the cross-linking of a functional compound, in particular a polymer comprising silane groups. In a...
|
|
WO/2018/115380A1 |
The present invention encompasses compounds of formula (I), wherein the groups R1 to R7 have the meanings given in the claims and specification, their use as inhibitors of SOS1, pharmaceutical compositions which contain compounds of this...
|
|
WO/2018/119183A2 |
Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
|
|
WO/2018/118668A1 |
Provided are novel salts and polymorphs of 5-(2,4-diamino-pyrimidin-5-yloxy)-4-isopropyl-2-methoxy-benz
enesulfonamide, which are potentially useful for modulating a condition mediated by a P2X3 or P2X2/3 receptor. Also provided are phar...
|
|
WO/2017/168447A9 |
The present invention discloses a cyclic compound of formula (I) and a process of preparation thereof. The present invention further discloses a process for the preparation of compound of formula (II) preferably Hunanamycin A from compou...
|
|
WO/2018/107201A1 |
The invention relates to functionalized dihydro— and tetrahydro-quinazoline compounds, pharmaceutical compositions comprising such compounds, and the use of such compounds as heparanase inhibitors for the treatment of diseases or condi...
|
|
WO/2018/108671A1 |
The present invention relates to the compounds of formula (I), and the N-oxides, stereoisomers, tautomers and agriculturally or veterinarily acceptable salts thereof wherein the variables are defined according to the description. The com...
|
|
WO/2018/111738A1 |
Disclosed herein are substituted pyrazole-pyrimidine compounds of Formula (I) and variants thereof for the treatment, for example, of diseases associated with P2X purinergic receptors. In one embodiment, the P2X3 and/or P2X2/3 antagonist...
|
